In: South African Medical Journal, 2016, vol. 106, no. 5, p. 449–450
The polymyxin antibiotic colistin is an antibiotic of last resort for the treatment of extensively drug-resistant Gram-negative bacteria, including carbapenemase- producing Enterobacteriaceae. The State of the World’s Antibiotics report in 2015 highlighted South Africa (SA)’s increasing incidence of these ‘superbugs’ (3.2% of Klebsiella pneumoniae reported from SA were carbapenemase...
|
In: Clinical Infectious Diseases, 2020, vol. 70, no. 9, p. 1998–2001
In July 2017, a patient presented colonization with a multidrug-resistant, carbapenemase (KPC-3)-producing Klebsiella pneumoniae isolate. A custom-made, lytic bacteriophage preparation was administered to the patient in December 2017, with subsequent eradication of the microorganism and without adverse effects.
|
In: Journal of Antimicrobial Chemotherapy, 2019, vol. 74, no. 9, p. 2666–2675
Objectives: In a new experimental model of carbapenemase-producing Klebsiella pneumoniae osteomyelitis we evaluated the efficacy of colistin alone and in various combinations and examined the emergence of colistin-resistant strains and cross- resistance to host defence peptides (HDPs).Methods: KPC-99YC is a clinical strain with intermediate susceptibility to meropenem (MIC = 4 mg/L) and...
|
In: Expert Review of Molecular Diagnostics, 2017, vol. 17, no. 4, p. 327–350
The rapid detection of resistance is a challenge for clinical microbiologists who wish to prevent deleterious individual and collective consequences such as (i) delaying efficient antibiotic therapy, which worsens the survival rate of the most severely ill patients, or (ii) delaying the isolation of the carriers of multidrug-resistant bacteria and promoting outbreaks; this last consequence is...
|
In: Clinical Microbiology and Infection, 2015, vol. 21, no. 2, p. e9–e10
|
In: Eurosurveillance, 2013, vol. 18, no. 31, p. 20547
We report the first outbreak of carbapenem-resistant NDM-1-producing Acinetobacter baumannii in Europe, in a French intensive-care unit in January to May 2013. The index patient was transferred from Algeria and led to the infection/colonisation of five additional patients. Concurrently, another imported case from Algeria was identified. The seven isolates were genetically indistinguishable,...
|
In: Microbial Drug Resistance, 2020, p. -
Objectives: To evaluate the biochemical Rapid ESBL NP® (Liofilchem, Italy) for the rapid detection of extended-spectrum β-lactamases (ESBLs) in Enterobacterales.Methods: A total of 100 clinical gram-negative strains (40 ESBL producers with or without cephalosporinase, 43 carbapenemase producers with or without additional ESBLs, 8 AmpC-type producers, 6 penicillinase producers, and 3 ...
|
In: Journal of Antimicrobial Chemotherapy, 2017, vol. 72, no. 10, p. 2787-2791
|
In: Journal of Antimicrobial Chemotherapy, 2017, p. -
Objectives: Plazomicin, a novel aminoglycoside with in vitro activity against MDR Gram-negative organisms, is under development to treat patients with serious enterobacterial infections. We evaluated the activity of plazomicin and comparators against colistin-resistant enterobacterial isolates.Methods: Susceptibility to plazomicin and comparators was tested by broth microdilution for a collection...
|
In: Microbial Drug Resistance, 2017, p. -
|
